anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain a new peptide and provide a method for producing the same, an angiotensin-converting enzyme inhibitor (ACE inhibitor) containing the new peptide as an effective component, a pharmaceutical composition containing the ACE inhibitor and health food or food.  &lt;P&gt;SOLUTION: The peptide comprises a specific L-amino acid sequence produced by decomposing a protein extracted from spirulina with a protease and isolating from the decomposed product. The ACE inhibitor contains the peptide as an effective component. The pharmaceutical composition, the health food and the food containing the ACE inhibitor are provided. The method for producing the peptide has processes to treat microalgae with a protease in an aqueous solution to extract peptides into the aqueous solution, subsequently remove water-insoluble materials in the aqueous solution and fractionate the obtained peptides.  &lt;P&gt;COPYRIGHT: (C)2008,JPO&amp;INPIT
A method of interfering with the interaction and/or function of α1-antichymotrypsin (ACT) and Alzheimer&#39;s β-protein and, as a result, reducing the adverse side effects associated with formation of a complex comprising the two or with activity of the complex components. In one embodiment, the subject invention relates to methods of interfering with formation of a specific complex between ACT and β-protein. In another embodiment, the present invention relates to methods of inhibiting the function of the components of the ACT-β-protein complex. In particular, it relates to methods of inhibiting the function of β-protein, particularly enzymatic activity, such as esterase (cholinesterase) or protease activity. Both methods are useful in treating or preventing the effects of complex formation or of the enzymatic activity of the β-protein and, thus, provide a potential method of treating or preventing Alzheimer&#39;s disease, Down&#39;s syndrome or normal aging. Compositions and compounds useful in the method are also the subject of this invention.
PROBLEM TO BE SOLVED: To obtain a medicinal agent for treatment or prevention of obesity by including a flavonoid compound as an active ingredient. SOLUTION: This medicinal agent contains a flavonoid compound of the formula [R&lt;1&gt; is H or OR (R is H, methyl, C(O)-(CH2 )2 -CH3 or a saccharide residue); R&lt;2&gt; and R&lt;3&gt; are each OR;(m) is 0-4;(n) is 0-5] or glycoside thereof. The compound of the formula is e.g. luteolin, apigenin. This medicinal agent is capable of inhibiting glycerophoshoric acid dehydrogenase whose activity rises when fat precursor cells differentiate into fat cells. This medicinal agent can be made into a parenterally administrable agent, its daily dose being 0.5-5,000mg/ adult or 0.5-3000mg/child. Food additives or foodstuffs formulated with this inhibitor can also be prepared.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to oncology, to nanoparticles based on biodegradable polymers with anticancer preparations encapsulated therein and can be used for treating malignant growths. Nanoparticles based on biodegradable polymers with anticancer preparations encapsulated therein are made in the form of spherical double-layer structures containing an outer insulating layer and inner spherical part made of biodegradable polymers selected from polyglycolide group, poly-DL-lactide, polylactide-glycolides (PLGA) containing 50 % of L-isomer and 50 % of D-isomer or polylactide-glycolides (PLGA), containing 85–90 % of L-isomer and 10–15 % of D-isomer, inner spherical part of two-layer structure is encapsulated in its volume with nanoparticles of anti-tumour preparations in amount of 36 to 54 wt. %. Antineoplastic preparations are selected from a group of fluorouracil, or a mixture of fluorouracil with exogenous siRNA205, or a mixture of fluorouracil with exogenous siRNA205 and cisplatin, or a mixture of fluorouracil with cisplatin. Nanoparticles of anti-tumour preparations can be adsorbed on the surface of the inner spherical part of the two-layer structure. Spherical nanoparticles are made with diameters of 10 to 200 nm, and thickness of outer insulating layer is selected depending on expected time of controlled delivery of anti-tumour preparations to affected tissue and makes 0.15–0.32 of external diameters of nanoparticles. Produced nanoparticles provide effective inhibition of growth of malignant growth, increased cytostatic activity and selective effect on tumour cells. Besides, obtained nanoparticles provide targeted effect of anti-cancer preparations on tumour cells without isolation of anticancer preparations in surrounding tissues during movement to tumour cells with simultaneous reduction of treatment time and reduced biochemical load on patient&#39;s body.EFFECT: invention provides high clinical effectiveness with obtaining a stable therapeutic effect ensured by the inhibitory effect on malignant growth.4 cl, 1 tbl, 3 dwg
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to surgical dentistry and is intended for application in carrying out vestibuloplastry. Horizontal cut of mucousa is performed on the boundary of alveolar gum and movable mucous envelope of oral cavity vestibule. Dissection of flap is performed parallel to periosteum. Mucous flap and muscles are displaced in apecal direction to the depth of created vestibule. On periosteum rewsidual muscular fibres and connective tissue bands are excised. De-epithelialisation of submarginal keratinised gum is performed within 1-2 mm. Sampling of free gum transplant of required length is carried out on hard palate in area from canine to second molar of maxilla, indenting 3-4 mm from gum edge. After sampling, autotransplant is exposed in preparation &#34;Perftoran&#34; for one minute. In recipient zone preparation &#34;Perftoran&#34; is introduced into transitional fold in dose 0.01 ml/kg of body weight. Transplant is fixed on periosteum bed. First sutures are applied on transplant edges, after that, sutures, fixing and stabilising lower and upper edges of transplant are performed with placement of upper edge of transplant on de-epithelialised surface of keratinised gum. After that, transplant is fixed by blanket suture, which presses it to periosteum bed. In the last turn edge of mucous flap is fixed in the depth of newly created vestibule of cavity. In post-operative period applications with preparation &#34;Perftoran&#34; are performed 1 time per day for ten minutes during 3 days. ^ EFFECT: method makes it possible to improve functional result, reduce quantity of post-operative complications, creates conditions for accelerated regeneration of tissues due to increase of zone of keratinised gum and reduction of risk of free gum transplant necrosis. ^ 1 ex
A unique composition of material for manufacturing a cleansing cream has an excellent cleansing effect of greasy dirt, pigments and cosmetic residues from human skin. The basic composition of material of this invention to render the cleansing effect of greasy dirt, pigments and cosmetic residues from human skin is composed of ducks&#39; fat oil and sodium carbonate, Na 2 CO 3 . The cleansing cream of this invention is excellent in cleansing greasy, viscous high molecular organic materials from not only human skin but also leathers, cloths, tiles, plastic and metal surfaces, by just pasting the cream and scrubbing. The cream can be wiped out with a tissue or cloth towel, rinsed with warm water. Alternatively, the cream can be allowed to stay on the skin and surface following the cleansing. The cleansing cream of this invention is non-toxic, non-allergic to human skin and environmentally affirmative. The cleansing cream of this invention is especially suitable for washing out of disguise pigments from a soldier&#39;s face.
The invention relates to formation of replicative cells from multipotential stem cells. As the most numerous cell type in the brain, astrocytes are coupled via gap junction channels. It is believed that communication among astrocytes is normally regulated by extracellular ions, neurotransmitters and neuromodulators. However, the level of astrocytic coupling is altered in abnormal conditions such as stroke, brain trauma and Alzheimer&#39;s disease. A well established human progenitor cell line, NT2/D1, has been previously differentiated into pure neuronal cultures. For the first time, we report the differentiation of NT2/D1 cells into astrocytes, which express connexin43 and are coupled via gap junctions. Thus, human NT2/D1 cells are not merely committed neuronal progenitors but, similar to the embryonal stem cells, they can give rise to both lineages. This has potential in treatment of various forms of neurological deficiency. Other replicative cells may be formed from multipotential stem cells according to the invention.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide an oxidation hair dye composition having excellent hair dyeing power, affording a natural hair dyed state and suppressing damage to hair without generating a gas during preservation in a vessel.  &lt;P&gt;SOLUTION: The oxidation hair dye composition comprises an oxidation dye and is used by mixing with an oxidizing agent composition. Furthermore, the oxidation hair dye composition comprises 1.0-8.0 mass% of (A) ascorbic acids and 0.3-8.0 mass% of (B) an ingredient which is an ammonium salt of an inorganic acid or an organic acid other than a carbonate generating the gas. As the ingredient (B), ammonium chloride, ammonium acetate, triammonium phosphate, etc., are specifically used. The ingredient (B) preferably has ≥20 g solubility in 100 g of water at 25°C for improving the hair dyeing power and further preventing the deposition of the ingredient (B) during preservation of the oxidation hair dye composition.  &lt;P&gt;COPYRIGHT: (C)2006,JPO&amp;NCIPI
NEW MATERIAL:An oligodeoxyribonucleotide expressed by the formula [P(S) is S atom bonded through a double bond to P atom of internucleotide part; P(O) is O atom bonded through a double bond to P atom of internucleotide part]. USE:A HIV activity inhibitor useful as a treating agent of AIDS. PREPARATION:An alcohol expressed by the formula [R&lt;1&gt; is C(CX3)3, CH(CX3)2 (X is halogen), etc.] is reacted with a compound expressed by the formula R&lt;2&gt;OPCl2 (R&lt;2&gt; is 1-6C alkyl) to afford a new phosphite compound expressed by the formula (R&lt;1&gt;O)2P(OR&lt;2&gt;). Then, a nucleotide unit having a base suitable for target sequence is introduced into a solid phase carrier on which nucleotide is fixed to carry out condensation reaction. Then, capping of unreacted 5&#39;-OH and solid phase carrier is carried out using the above-mentioned phosphite compound as a capping agent. The reaction is successively repeated to synthesize the objective sequence having a base sequence and then sulfur oxidation and final deprotection are carried out.
The invention discloses a Chaiping soup for treating post-laparscopic cholecystectomy blocked dynamic and a preparation method thereof. The preparation method comprises compounding radix bupleuri, pinellia, officinal magnolia bark, stir-fried baical skullcap root, prepared rhizoma atractylodis, orange peel, gentian, banksia rose, bitter orange, white peony root, corydalis tuber, curcuma tuber, fresh ginger, honey-fried licorice root and purified water into a soup, carrying out decoction by an automatic drug-decocting machine for 20min, carrying out squeezing, carrying out filtration by a nylon sieve VI (having the size of 150+/-6.6 microns) of 100 meshes to obtain 300ml of the Chaiping soup, dividing equally 300ml of the extracted Chaiping soup into two parts, wherein each one of the two parts has a volume of 150ml, and carrying out vacuum packaging, wherein a vacuum package material has the thickness of 0.15 to 0.20mm. 150ml of the Chaiping soup is taken by a patient every time. The Chaiping soup is a warm-taken decoction and is taken at morning and evening. A treatment course comprises two weeks. The Chaiping soup has effects of soothing liver-qi stagnation, harmonizing stomach for descending adverse qi, promoting qi circulation to relieve pain, relaxing oddi&#39;s sphincter and reducing pressure of the bile duct, and has symptom relieving total efficiency of 93.8%.
PURPOSE: To produce an aloe juice by extracting an aloe gel containing substantially no anthraquinonc from a leaf of aloe plant. CONSTITUTION: A leaf of an aloe plant is washed with an antiseptic solution (e.g. an aqueous solution of calcium hypochlorite) to remove a soil and bacteria on the surface of the leaf. A juice rich in anthraquinone is obtained by removing the tip part and base part of the washed leaf, and leaving and allowing the removed leaf to drain the juice. Further, the resultant leaf is taken out from the solution, and hull of the leaf is removed to provide an aloe gel fillet. The aloe gel fillet is ground and homogenized to provide the objective aloe juice containing substantially no anthraquinone, that is about &lt;0.001 wt.% thereof. Preferably, a fibrous material is removed from the aloe juice by filtration. The aloe juice is formulated with many kinds of products for internal use and external use, e.g. cosmetics, health foods and drinks, medicines.
An immune-peroxidase test for serologic diagnostics of porcine reproductive and respiratory syndrome virus includes inoculation of cells of sensitive culture to 96-well plastic microplates with flat bottom; dilution of test serums by the method of two-fold dilution with addition of working dilution of reproductive and respiratory syndrome virus in the 96-well plastic microplates with round bottom with following contact of those and with bringing to the holes of the microplate with mono-layer of cell culture; incubation during seven days under conditions of COincubator; removal from the microplate wells of the culture medium, with washing the cell mono-layer; introduction of fixing buffer to all the microplate wells; step-by-step introduction to all the microplate wells – working dilution of specific blood serum, working dilution of conjugate, solution of substrate; termination of reaction through adding stop-solution to each well of the table and registration of reaction under inverted light microscope based on the principle of presence or absence of specific dyeing of the cells – infected cells look like single cells or groups of cells (plaques) with cytoplasm dyed to dark-red color and light nucleus. For reveal of specific humoral antibodies against the reproductive and respiratory syndrome virus in domestic and wild hog biological material (serum of blood, milk, colostrums) is determined. For cultivation sensitive to reproductive and respiratory syndrome virus cell cultures (CL 2621, MA-104, MARC-145) are used; grown in cultural vessels (glass or plastic pads). The cell monolayer is taken by means of solution of trypsin-versen at ratio 1:9. For cultivation of cell culture, 7-10 % of embryo blood serum of cattle is added to nutrient media. The test blood serums before investigation undergo inactivation at temperature during 30 minutes with titration with the method of double dilution with adding working dilution 1000 U of reproductive and respiratory syndrome virus (reference - &#34;Lelystad&#34;, &#34;Hesse&#34; or deposited strains) with exposition during one hour at +; content is added to the microplate wells with the sensitive culture of cells with pre-grown (48-72 hours) mono-layer with addition of 2 % embryo serum of cattle blood. As control virus the reference or deposited strains of reproductive and respiratory syndrome virus are used. At fixation of mono-layer of cells 96 % ethyl alcohol is used. Porcine specific blood serum against the reproductive and respiratory syndrome virus is used as working dilution of positive serum. Tvin-20 is not used when monolayer is washed. At termination of reaction – NaCL; all manipulations with drying the cell mono-layer are carried out under conditions of thermostat at temperature and exposition – one hour. While recording of the reaction the presence of plaque – absence of antibodies, and the absence of plaque – presence of anti-bodies against the reproductive and respiratory syndrome virus in porcine blood serums are taken into account.
PURPOSE: To provide a safe and novel immune agent which consists of the pure capsule polysaccharides formed by making the lipopolysaccharide contained therein nontoxic by a treatment with a deacylating agent and is useful for active immunity to a Klebsiella infection. CONSTITUTION: The polyvalent immune pharmaceutical prepn. consisting of a nontoxic serum type specific polysaccharide prepn. Namely, the refined capsule polysaccharide(CPS) derived from the bacteria of Klebsiella species are treated with the deacylating agent, such as potassium hydroxide, by which the nonexothermic immunogenic CPS pharmaceutical prepn. is obtd. The Klebsiella infectious disease may be prevented by using the immunogenic Klebsiella species CPS. The capsule polysaccharides are preferably refined from the clean matter in terms of culture of the Klebsiella cultured in a medium consisting of 1 to 5% pie cases S, F, 0.1 to 1% yeast extract and 1 to 10% maltose. The average mol.wt. of the capsule polysaccharide is preferably 1×10&lt;6&gt; dalton. The vaccine is nonorally medicated in order to increase the serum antibody level to the CPS.
A digital camera containing patient images is connected to an uploader computer and the patient&#39;s name or history is entered into the uploader computer. The uploader computer then connects to the Internet, connects to the secure host server, uploads the images to the host server and shuts down the Internet connection. After the physician selects a medical facility and the system verifies the physician&#39;s user I.D. and password, the host server constructs an HTML web page which includes a list of patients whose images were previously uploaded by the medical facility and are available for viewing. The physician simply selects the name of a patient and the host server displays the patient information and images on the physician&#39;s computer. The system is password-protected at all levels and the operator for each medical facility determines who may have access to the medical facility images.
A method for the propagation of protozoa of the genus Theileria comprises the propagation of host cells containing the agamonts of the protozoa in association with a concurrent propagation of a tissue culture cell line not infectible with the protozoa, as a mixed culture carried out in an aqueous nutrient medium.  The tissue culture cell line may be the baby hamster kidney cell line BHK 21. The host cells may be blood leucocytes from an infected calf in the case of T. annulata or cells from the spleen or lymph nodes of an infected steer in the case of T. parva.  A typical culture medium comprises a mixture of borine serum, tryptose phosphate broth and Eagle&#39;s basal medium, preferably with an increased aminoacid and vitamin content.  The mixed culture may be sub-cultured by the monolayer culture technique. The mixed culture may be administered to cattle to render them immune to theileriasis.ALSO:A vaccine comprises living protozoa of the germs Theileria which have been propagated in host cells concurrently with a tissue culture cell line not infectible with the protozoa as a mixed culture in an aqueous nutrient medium.  The host cells may be blood leucocytes from an infected calf in the case of T. annulata or cells from the spleen of lymph nodes of an infected steer in the case of T. parva.  The tissue culture cell line may be baby hamster kidney cells BHK 21, which have been trypsinised. The culture medium contains the usual nutrients required in the p  propagation of animal cells, e.g. it may comprise a mixture of bovine serum, tryptose phosphate broth and Eagle&#39;s basal medium, preferably with an increased amino-acid and vitamin content. The mixed culture may be sub-cultured by the monolayer culture technique.  The protozoa is propagated by incubation of the mixed culture at 37-40 DEG C. and by successive transfers of the propagated mixed cell culture into a new culture medium, e.g. every third or fourth day.  The mixed tissue culture obtained by sub-culturing may be centrifuged and resuspended.  The suspension may be used as a vaccine for administration to cattle to render them immune to theileriasis.
NEW MATERIAL:A compound expressed by formula I (M is H or salt-forming residue; R&lt;1&gt; and R&lt;2&gt; are lower alkyl). EXAMPLE:4-(Bis-isopropoxycarbonyl)methylene-1,3-dithietane-2-carboxylic acid. USE:Useful as an activating agent for the hepatic function and remedy for hepatic diseases, e.g. fatty liver, alcoholic hepatitis, hepatitis, toxic hepatopathy, cardiac cirrhosis, cholestatic hepatopathy or cirrhosis, of warm-blooded animals having activating action on the hepatic function. PROCESS:A malonic diester expressed by formula II is reacted with carbon disulfide in the presence of an alkali to give a dithiolate expressed by formula III(M&lt;1&gt; is Na or K), which is then isolated or without the isolation reacted with dichloroacetic acid to afford a compound expressed by formula I (M is H). The resultant compound is then converted into a pharmacologically acceptable salt, e.g. Na or Ca salt, thereof.
The invention discloses use of 5,6,7,4&#39;-tetra-acetoxyl flavone for preparing a medicine for preventing and curing cardiovascular and cerebrovascular diseases, relating to the medical field. The pharmacological tests show that the 5,6,7,4&#39;-tetra-acetoxyl flavone can obviously improve behavior disorders of cerebral ischemic rat, reduce the area of cerebral infarction, improve the cerebral ischemia symptoms, and obviously protect the cerebral ischemia damages. The rat platelet aggregation can be obviously inhibited so as to inhibit the forming of thrombus in vivo. The 5,6,7,4&#39;-tetra-acetoxyl flavone with different dosages can reduce the viscosity of whole blood of the rat, viscosity of plasma and hematokrit. The 5,6,7,4&#39;-tetra-acetoxyl flavone can prolong the mouse blood coagulation time, has the dose-dependence, and can reducethe positive rate of rat myocardial ischemia caused by the pituitrin. The 5,6,7,4&#39;-tetra-acetoxyl flavone is further featured with low toxicity and high safety, and has good application foreground for treating and preventing the cardiovascular disease.
PCT No. PCT/FR92/00317 Sec. 371 Date Jan. 14, 1993 Sec. 102(e) Date Jan. 14, 1993 PCT Filed Apr. 10, 1992 PCT Pub. No. WO92/20646 PCT Pub. Date Nov. 26, 1992.The invention relates to the field of organic chemistry and more particularly to that of therapeutic chemistry. More particularly it relates to new quaternary ammonium salts of general formula (I):    &lt;IMAGE&gt;  (I)  in which Hal is a halogen atom other than fluorine R and R1, identical or different, are lower alkyl radicals, n is an integer varying from 2 to 16, Z is an alkenyl radical having up to 3 carbon atoms, a carboxyl, or the OR2 group in which R2 is a hydrogen, a lower alkyl radical, an acyl remainder, a tocol radical, a sterol radical or a carboxamide chain and A is a hydroxyl or an anion of a mineral or organic acid. The compounds according to the invention are the active ingredients of pharmaceutical compositions with an anti-tumorous and/or immuno-suppressive action.
FIELD: organic chemistry, virology, pharmacy. SUBSTANCE: invention describes the novel derivatives of benzothiophene, benzofuran, indolethiazepinone, oxazepinone and diazepinone of the formula (I) &lt;EMI ID=0.1 HE=37 WI=53 TI=CHI&gt; where: R1-R6, X and Y have values given in p. 1 of the invention claim, and their pharmaceutically acceptable acid-additive salts. The proposed heterocyclic compounds can be used as an active component of a pharmaceutical composition showing capacity to inhibit cellular adhesion or HIV-activity. Except for, these compounds can be used for inhibition of leukocytes adhesion to endothelial cells in treatment of sicknesses caused with its, for example, inflammatory sickness and also for treatment of humans and animals infected with HIV-infection. EFFECT: new compounds indicated above, enhanced effectiveness of treatment. 15 cl, 2 tbl, 12 ex